For the year ending 2025-12-31, AURA had $28,008K increase in cash & cash equivalents over the period. -$85,189K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -106,191 |
| Depreciation expense | 1,129 |
| Accretion income on marketable securities | 1,546 |
| Other non-cash items | 27 |
| Stock-based compensation expense | 14,317 |
| Non-cash lease expense | 1,551 |
| Prepaid expenses and other assets | -4,031 |
| Other long-term assets | -47 |
| Accounts payable | -846 |
| Accrued expenses and other liabilities | 4,131 |
| Operating lease liabilities | -1,392 |
| Net cash used in operating activities | -84,742 |
| Purchases of property and equipment | 447 |
| Purchases of marketable securities | 83,958 |
| Maturities of marketable securities | 120,000 |
| Net cash provided by investing activities | 35,595 |
| Proceeds from exercise of stock options | 1,010 |
| Proceeds from issuance of common stock from follow-on offering, net of issuance costs | 46,517 |
| Proceeds from issuance of pre-funded warrants from follow-on offering, net of issuance costs | 14,156 |
| Proceeds from issuance of common stock warrants from follow-on offering, net of issuance costs | 9,254 |
| Proceeds from issuance of common stock under atm facility, net of issuance costs | 6,054 |
| Proceeds from espp purchases | 164 |
| Net cash provided by financing activities | 77,155 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 28,008 |
| Effect of exchange rate changes on cash and cash equivalents | -186 |
| Cash, cash equivalents and restricted cash at beginning of period | 32,461 |
| Cash, cash equivalents and restricted cash at end of period | 60,283 |
Aura Biosciences, Inc. (AURA)
Aura Biosciences, Inc. (AURA)